Elsevier Conferences – Covid 19 Policy
We look forward to welcoming our conference delegation back and are committed to your health and safety, whilst attending our events. Keeping our conferences safe is a shared responsibility and we ask all participants play their part in making the conference as safe as reasonably practical.
Please be advised that a risk of exposure to Covid-19 exists in any event or public space, including the conference. Prior to registering for and attending the conference, please ensure you have read the latest guidelines for USA and South Carolina , https://scdhec.gov/covid19
Attendees at the 4th International Brain Stimulation Conference will be required to:
By attending the conference, you acknowledge this inherent risk and, as a condition of entering the conference, you acknowledge, understand and confirm that you will comply with the following guidance:
- That you will abide by all the International Brain Stimulation Conferences health-and-safety requirements;
- That you are not currently experiencing any of the following symptoms of COVID-19, as identified at CDC.gov, including, but not limited to:
- Fever or chills
- Shortness of breath or difficulty breathing
- Muscle or body aches
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- That prior to attending the International Brain Stimulation Conference you have not been in contact with someone with confirmed or suspected COVID-19 symptoms without completing a 14-day quarantine; and
- That you are not under any self-quarantine order
- That you are fully vaccinated, meaning at the time you are attending the Event it has been at least fourteen (14) days since:
- your second dose in a 2-dose COVID-19 vaccine series approved or authorized by the FDA or by the WHO, or
- your single dose of a single-dose COVID-19 vaccine authorized by the FDA or by the WHO
Please do not enter the conference or the venue if you cannot confirm all of the above. If at any point during your time at the conference you do not meet all of the above criteria, you will be required to isolate and asked to leave the conference venue, at management's sole discretion.
To reiterate, to protect the health and safety of all our conference attendees, Elsevier requires proof of WHO approved Covid-19 vaccinations to be eligible to attend. This will be coupled with mask wearing throughout the conference.
Please make sure you have your proof of vaccination paperwork, ready to be checked by security staff, prior to entering the conference venue. Entry will NOT be granted without the appropriate vaccination paperwork and no refunds will be given for failure to produce this.
Additional measures to be taken by Elsevier and the conference venue, for your safety:
- Hand sanitiser will be available throughout the venue, for all conference areas (meeting rooms, exhibit areas, catering points, poster rooms and common areas
- Increased cleaning measures, to ensure that all high-contact areas will be frequently sanitised
- Compliance with venue capacity limits: We will ensure that maximum capacity limits are complied with in exhibition halls, conference spaces and food service areas.
- Safety reminders: All participants will be regularly reminded of the conference safety measures, via the dedicated conference app
Prior to registering for and attending the conference, please ensure you have read the latest United States guidelines for prevention: https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html
Before travelling to Charleston, SC, USA, please make sure that you have reviewed any advisories and restrictions that may be in place, for travel to the conference location: Coronavirus Disease 2019 (COVID-19) | SCDHEC
For information on what the conference venue is doing to keep you safe during the conference, please read here: https://whattoexpect.marriott.com/chsmc
Finally, we are asking everyone to keep your distance where you can and respect others, who may be apprehensive returning to live events. Thank you for your co-operation, we are looking forward to returning to live conferences safely.